This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

3 days ago 6

Jonathan Ponciano, The Motley Fool

Sun, May 17, 2026 astatine 1:42 PM CDT 4 min read

HighVista Strategies sold 69,092 shares of Structure Therapeutics (NASDAQ:GPCR) successful the archetypal quarter, an estimated $4.73 cardinal commercialized based connected quarterly mean pricing, per the May 15, 2026 SEC filing.

What happened

According to an SEC filing dated May 15, 2026, HighVista Strategies reduced its holding successful Structure Therapeutics by 69,092 shares during the archetypal quarter. The estimated transaction worth was $4.73 million, calculated utilizing the mean closing terms for the quarter. The position’s quarter-end worth decreased by $7.45 million, a fig that incorporates some the stock merchantability and marketplace terms fluctuations.

What other to cognize

This was a sell; post-trade, the Structure Therapeutics involvement represents 1.6491% of HighVista’s reportable U.S. equity AUM
Top holdings aft the filing:
- NYSEMKT:DBC: $30.61 cardinal (8.5% of AUM)
- NASDAQ:ABVX: $12.61 cardinal (3.5% of AUM)
- NASDAQ:PRAX: $8.48 cardinal (2.3% of AUM)
- NASDAQ:COGT: $7.58 cardinal (2.1% of AUM)
- NASDAQ:SYRE: $7.38 cardinal (2.0% of AUM)
As of May 14, 2026, shares of Structure Therapeutics were priced astatine $39.84, up astir 60% implicit the past twelvemonth and good outperforming the S&P 500’s astir 25% summation successful the aforesaid period.

Company Overview

Metric

Value

Price (as of marketplace adjacent 2026-05-14)	$39.84
Market Capitalization	$2.8 billion
Net Income (TTM)	($141.2 million)
One-Year Price Change	60%

Company Snapshot

Structure Therapeutics develops oral therapeutics targeting chronic diseases, with pb campaigner GSBR-1290 for type-2 diabetes and obesity, and further pipeline assets for pulmonary and cardiovascular indications.
The institution operates a clinical-stage biopharmaceutical concern exemplary focused connected proprietary research, development, and out-licensing oregon commercialization of caller tiny molecule drugs targeting G-protein-coupled receptors (GPCRs).
It targets healthcare providers, biopharma partners, and patients with unmet aesculapian needs successful metabolic, pulmonary, and cardiovascular illness segments.

Structure Therapeutics Inc. is simply a clinical-stage biotechnology institution specializing successful the improvement of innovative oral tiny molecule therapeutics for chronic diseases with important unmet need. The company's strategy leverages expertise successful GPCR biology to beforehand a pipeline of differentiated oral therapeutics for chronic diseases. With a absorption connected metabolic and pulmonary indications, Structure Therapeutics seeks to found a competitory borderline done proprietary cause plan and a robust objective improvement program.

What this transaction means for investors

Structure Therapeutics shares person climbed astir 60% implicit the past twelvemonth arsenic investors piled into companies processing next-generation GLP-1 therapies, particularly oral alternatives to injectable weight-loss drugs. With that benignant of run, it doesn’t look astonishing for a money to see rebalancing.

For its part, the institution has continued delivering beardown objective updates. Earlier this month, Structure reported Phase 2 information showing up to 16.3% placebo-adjusted value nonaccomplishment astatine 44 weeks for oral obesity campaigner aleniglipron, which absorption said compares favorably with injectable GLP-1 therapies. The institution besides said it received affirmative end-of-Phase 2 FDA feedback and remains connected way to motorboat Phase 3 trials successful the 3rd quarter.

Separately, Structure ended March with astir $1.5 cardinal successful cash, currency equivalents, and short-term investments, which absorption says should money operations done the extremity of 2028.

Ultimately, the cardinal question is whether oral GLP-1 drugs tin carve retired a meaningful portion of a marketplace presently dominated by injectable therapies. High expectations are already baked into galore obesity stocks, but Structure’s increasing objective information bundle suggests the institution remains 1 of the much superior contenders successful the space.

Read Entire Article